ConforMIS Inc (CFMS) CEO Sells $11,226.52 in Stock
ConforMIS Inc (NASDAQ:CFMS) CEO Mark A. Augusti sold 4,189 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $2.68, for a total transaction of $11,226.52. Following the completion of the sale, the chief executive officer now directly owns 236,163 shares in the company, valued at approximately $632,916.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of ConforMIS Inc (CFMS) traded down $0.15 on Wednesday, hitting $2.45. 550,778 shares of the company traded hands, compared to its average volume of 324,209. The company has a current ratio of 6.19, a quick ratio of 5.38 and a debt-to-equity ratio of 0.52. ConforMIS Inc has a fifty-two week low of $2.43 and a fifty-two week high of $9.47.
ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. The firm had revenue of $18.40 million during the quarter, compared to analyst estimates of $17.55 million. During the same quarter in the prior year, the business posted ($0.31) earnings per share. ConforMIS’s revenue for the quarter was down 1.3% compared to the same quarter last year. equities analysts predict that ConforMIS Inc will post -1.27 EPS for the current year.
Several brokerages have issued reports on CFMS. ValuEngine raised shares of ConforMIS from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. BTIG Research reissued a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. Finally, Zacks Investment Research downgraded shares of ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $5.85.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.